lifestyle.longislandreport.org

Author: Santhera Pharmaceuticals Holding AG

Full Year 2025 Trading Update

March 12, 2026
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth

March 10, 2026
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy

March 9, 2026
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy

February 27, 2026
Santhera Appoints Stifel as Corporate Finance Advisor

February 12, 2026